Vegf antagonist formulations suitable for intravitreal administration
US-2025257118-A1 · Aug 14, 2025 · US
This page is not indexed by search engines while we improve data quality.
Dix Daniel patents
Dix Daniel is listed as an inventor on 32 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Dix Daniel |
| Total patents | 32 |
| First publication | Mar 19, 2015 |
| Latest publication | Aug 14, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
VEGF antagonist formulations suitable for intravitreal administration
US-12331099-B2 · Jun 17, 2025 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2025042972-A1 · Feb 6, 2025 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2023374108-A1 · Nov 23, 2023 · US
VEGF antagonist formulations suitable for intravitreal administration
US-11732024-B2 · Aug 22, 2023 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2021340220-A1 · Nov 4, 2021 · US
VEGF antagonist formulations suitable for intravitreal administration
US-11084865-B2 · Aug 10, 2021 · US
Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
US-11071780-B2 · Jul 27, 2021 · US
VEGF antagonist formulations suitable for intravitreal administration
US-11066458-B2 · Jul 20, 2021 · US
Stabilized Formulations Containing Anti-NGF Antibodies
US-2021107974-A1 · Apr 15, 2021 · US
Recent patents
Latest publications not already listed above.
Vegf antagonist formulations suitable for intravitreal administration
US-2020131246-A1 · Apr 30, 2020 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2020017572-A1 · Jan 16, 2020 · US
VEGF antagonist formulations suitable for intravitreal administration
US-10464992-B2 · Nov 5, 2019 · US
VEGF antagonist formulations suitable for intravitreal administration
US-10400025-B2 · Sep 3, 2019 · US
Process for reducing subvisible particles in a pharmaceutical formulation
US-2019231877-A1 · Aug 1, 2019 · US
Process for reducing subvisible particles in a pharmaceutical formulation
US-10342876-B2 · Jul 9, 2019 · US
Methods and formulations for treating vascular eye diseases
US-2019117767-A1 · Apr 25, 2019 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2019031735-A1 · Jan 31, 2019 · US
Stabilized formulations containing anti-ngf antibodies
US-2019010222-A1 · Jan 10, 2019 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2018155408-A1 · Jun 7, 2018 · US
VEGF antagonist formulations suitable for intravitreal administration
US-9914763-B2 · Mar 13, 2018 · US
Stabilized formulations containing anti-DLL4 antibodies
US-9675692-B2 · Jun 13, 2017 · US
Methods and formulations for treating vascular eye diseases
US-2017080086-A1 · Mar 23, 2017 · US
Stable VEGF antagonist formulations
US-9511140-B2 · Dec 6, 2016 · US
Stable liquid formulations of dimer VEGF antagonists
US-9416167-B2 · Aug 16, 2016 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2016213608-A1 · Jul 28, 2016 · US
Vegf antagonist formulations
US-2016175439-A1 · Jun 23, 2016 · US
Methods and formulations for treating vascular eye diseases
US-2016144025-A1 · May 26, 2016 · US
VEGF antagonist formulations for intravitreal administration
US-9340594-B2 · May 17, 2016 · US
Process for reducing subvisible particles in a pharmaceutical formulation
US-2016101181-A1 · Apr 14, 2016 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Regeneron Pharma | 32 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61K47/26 | 31 |
| A61K47/02 | 25 |
| A61K38/179 | 25 |
| C07K2319/30 | 25 |
| A61P43/00 | 25 |